155 related articles for article (PubMed ID: 26897089)
1. Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists.
Lotesta SD; Marcus AP; Zheng Y; Leftheris K; Noto PB; Meng S; Kandpal G; Chen G; Zhou J; McKeever B; Bukhtiyarov Y; Zhao Y; Lala DS; Singh SB; McGeehan GM
Bioorg Med Chem; 2016 Mar; 24(6):1384-91. PubMed ID: 26897089
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.
Ogawa AK; Bunte EV; Mal R; Lan P; Sun Z; Crespo A; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Jochnowitz N; Ma X; Pan Y; Brown P; Zamlynny B; Bateman T; Leung D; Xu L; Tong X; Liu K; Crook M; Sinclair P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2866-2869. PubMed ID: 27161805
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.
Cox JM; Chu HD; Yang C; Shen HC; Wu Z; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2014 Apr; 24(7):1681-4. PubMed ID: 24630411
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.
Nordqvist A; O'Mahony G; Fridén-Saxin M; Fredenwall M; Hogner A; Granberg KL; Aagaard A; Bäckström S; Gunnarsson A; Kaminski T; Xue Y; Dellsén A; Hansson E; Hansson P; Ivarsson I; Karlsson U; Bamberg K; Hermansson M; Georgsson J; Lindmark B; Edman K
ChemMedChem; 2017 Jan; 12(1):50-65. PubMed ID: 27897427
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Ohyabu N; Ohra T; Fuji K; Sugimoto T; Fujimoto J; Asano K; Oosawa M; Shiotani S; Nishigaki N; Kusumoto K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2014 Oct; 22(19):5428-45. PubMed ID: 25187277
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists.
Yang C; Shen HC; Wu Z; Chu HD; Cox JM; Balsells J; Crespo A; Brown P; Zamlynny B; Wiltsie J; Clemas J; Gibson J; Contino L; Lisnock J; Zhou G; Garcia-Calvo M; Bateman T; Xu L; Tong X; Crook M; Sinclair P
Bioorg Med Chem Lett; 2013 Aug; 23(15):4388-92. PubMed ID: 23777778
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists.
Hasui T; Ohra T; Ohyabu N; Asano K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2013 Oct; 21(19):5983-94. PubMed ID: 23958516
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists.
Futatsugi K; Piotrowski DW; Casimiro-Garcia A; Robinson S; Sammons M; Loria PM; Banker ME; Petersen DN; Schmidt NJ
Bioorg Med Chem Lett; 2013 Dec; 23(23):6239-42. PubMed ID: 24157365
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
Takahashi M; Ubukata O; Homma T; Asoh Y; Honzumi M; Hayashi N; Saito K; Tsuruoka H; Aoki K; Hanzawa H
FEBS Lett; 2020 May; 594(10):1615-1623. PubMed ID: 31991486
[TBL] [Abstract][Full Text] [Related]
10. Facile synthesis of spirooxindole-pyrazolines and spirobenzofuranone-pyrazolines and their fungicidal activity.
Yang C; Li J; Zhou R; Chen X; Gao Y; He Z
Org Biomol Chem; 2015 May; 13(17):4869-78. PubMed ID: 25765334
[TBL] [Abstract][Full Text] [Related]
11. Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.
Roos K; Hogner A; Ogg D; Packer MJ; Hansson E; Granberg KL; Evertsson E; Nordqvist A
J Comput Aided Mol Des; 2015 Dec; 29(12):1109-22. PubMed ID: 26572910
[TBL] [Abstract][Full Text] [Related]
12. Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain.
Chowdhury S; Chafeev M; Liu S; Sun J; Raina V; Chui R; Young W; Kwan R; Fu J; Cadieux JA
Bioorg Med Chem Lett; 2011 Jun; 21(12):3676-81. PubMed ID: 21570288
[TBL] [Abstract][Full Text] [Related]
13. (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.
Bell MG; Gernert DL; Grese TA; Belvo MD; Borromeo PS; Kelley SA; Kennedy JH; Kolis SP; Lander PA; Richey R; Sharp VS; Stephenson GA; Williams JD; Yu H; Zimmerman KM; Steinberg MI; Jadhav PK
J Med Chem; 2007 Dec; 50(26):6443-5. PubMed ID: 18038968
[TBL] [Abstract][Full Text] [Related]
14. Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
Martín-Martínez M; Pérez-Gordillo FL; Álvarez de la Rosa D; Rodríguez Y; Gerona-Navarro G; González-Muñiz R; Zhou MM
J Med Chem; 2017 Apr; 60(7):2629-2650. PubMed ID: 28051871
[TBL] [Abstract][Full Text] [Related]
15. A facile chemo-, regio- and stereoselective synthesis and cholinesterase inhibitory activity of spirooxindole-pyrrolizine-piperidine hybrids.
Kia Y; Osman H; Kumar RS; Murugaiyah V; Basiri A; Perumal S; Razak IA
Bioorg Med Chem Lett; 2013 May; 23(10):2979-83. PubMed ID: 23570788
[TBL] [Abstract][Full Text] [Related]
16. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.
Bärfacker L; Kuhl A; Hillisch A; Grosser R; Figueroa-Pérez S; Heckroth H; Nitsche A; Ergüden JK; Gielen-Haertwig H; Schlemmer KH; Mittendorf J; Paulsen H; Platzek J; Kolkhof P
ChemMedChem; 2012 Aug; 7(8):1385-403. PubMed ID: 22791416
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants of ligand binding to the mineralocorticoid receptor.
Huyet J; Pinon GM; Fay MR; Rafestin-Oblin ME; Fagart J
Mol Cell Endocrinol; 2012 Mar; 350(2):187-95. PubMed ID: 21820032
[TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid receptor modulators: a patent review (2007 - 2012).
Collin M; Niemann F; Jaisser F
Expert Opin Ther Pat; 2014 Feb; 24(2):177-83. PubMed ID: 24215301
[TBL] [Abstract][Full Text] [Related]
19. Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.
Baxter JD; Funder JW; Apriletti JW; Webb P
Mol Cell Endocrinol; 2004 Mar; 217(1-2):151-65. PubMed ID: 15134814
[TBL] [Abstract][Full Text] [Related]
20. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Rogerson FM; Yao Y; Smith BJ; Fuller PJ
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
